Please login to the form below

Not currently logged in
Email:
Password:

PRV

This page shows the latest PRV news and features for those working in and with pharma, biotech and healthcare.

Alexion uses priority review voucher for Soliris follow-up

Alexion uses priority review voucher for Soliris follow-up

Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a coveted priority review voucher (PRV) to accelerate ... Alexion is sitting on a pair of PRVs awarded for earlier approvals for

Latest news

  • Sanofi pays $245m for FDA priority review voucher Sanofi pays $245m for FDA priority review voucher

    Sanofi pays $245m for FDA priority review voucher. PRV reduces review time from ten to six months. ... The French pharma major is paying small US drugmaker Retrophin $245m for the priority review voucher (PRV), awarded as an incentive for carrying out

  • J&J files new resistant TB drug bedaquiline in US

    The PRV would allow J&J to request priority review for another of its marketing applications. ... J&J was the first company to make use of a PRV after being awarded one for the approval of its antimalarial treatment Coartem (artemether/lumefantrine) in

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy. ... Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv

  • Pharma deals in August 2015 Pharma deals in August 2015

    In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report. ... Keeping this trend, United Therapeutics has sold a PRV to AbbVie for a headline value of

  • Pharma deals in May 2015 Pharma deals in May 2015

    The paediatric PRV was issued when Cholbam was approved for the treatment of patients with peroxismal disorders. ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam [cholic acid] in bile acid disorders.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Introduced by the FDA in 2007, a PRV is an incentive for companies to invest in treatments for neglected tropical diseases. ... Selling PRVs is a relatively new area and so these two deals provide initial benchmarks, however it will be interesting to see

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics